NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-0-13-1357-1111
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees21
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable
NuCana (NASDAQ:NCNA) Frequently Asked Questions
What is NuCana's stock symbol?
NuCana trades on the NASDAQ under the ticker symbol "NCNA."
How were NuCana's earnings last quarter?
NuCana PLC (NASDAQ:NCNA) released its earnings results on Wednesday, November, 13th. The company reported ($12.00) earnings per share for the quarter, topping the consensus estimate of ($22.80) by $10.80. View NuCana's Earnings History.
When is NuCana's next earnings date?
What price target have analysts set for NCNA?
5 analysts have issued 12-month price objectives for NuCana's shares. Their forecasts range from $15.00 to $25.00. On average, they anticipate NuCana's stock price to reach $19.00 in the next year. This suggests a possible upside of 192.8% from the stock's current price. View Analyst Price Targets for NuCana.
What is the consensus analysts' recommendation for NuCana?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NuCana.
What are Wall Street analysts saying about NuCana stock?
Here are some recent quotes from research analysts about NuCana stock:
- 1. According to Zacks Investment Research, "NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. " (11/14/2019)
- 2. HC Wainwright analysts commented, "We have valued NuCana on a discounted cash flow (DCF) basis, which yields a $624M projected enterprise value as of mid-2020. Our calculations rely upon a 60% probability of approval for Acelarin across both front-line BTC and fourth-line 30% probability of approval for NUC-3373 in the mCRC indication. We utilize a 12% discount rate and 17% effective corporate income tax rate, along with a 1% terminal growth rate." (8/19/2019)
Has NuCana been receiving favorable news coverage?
News articles about NCNA stock have been trending very negative this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. NuCana earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for NuCana.
Who are some of NuCana's key competitors?
Some companies that are related to NuCana include Omeros (OMER), Revance Therapeutics (RVNC), Kura Oncology (KURA), ANI Pharmaceuticals (ANIP), Collegium Pharmaceutical (COLL), Flexion Therapeutics (FLXN), Homology Medicines (FIXX), Emisphere Technologies (EMIS), Viking Therapeutics (VKTX), Akero Therapeutics (AKRO), DiaMedica Therapeutics (DMCAF), BioDelivery Sciences International (BDSI), Retrophin (RTRX), Myovant Sciences (MYOV) and Advanz Pharma (CXRXF).
What other stocks do shareholders of NuCana own?
Who are NuCana's key executives?
NuCana's management team includes the folowing people:
- Prof. Christopher B. Wood, Chairman & Chief Medical Officer (Age 73)
- Mr. Hugh S. Griffith, Founder, CEO & Director (Age 51)
- Mr. Donald Munoz, Chief Financial Officer (Age 50)
When did NuCana IPO?
(NCNA) raised $100 million in an IPO on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager.
Who are NuCana's major shareholders?
NuCana's stock is owned by many different of institutional and retail investors. Top institutional investors include Rothschild Investment Corp IL (0.08%).
Which institutional investors are selling NuCana stock?
NCNA stock was sold by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL.
How do I buy shares of NuCana?
Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is NuCana's stock price today?
One share of NCNA stock can currently be purchased for approximately $6.49.
How big of a company is NuCana?
NuCana has a market capitalization of $209.37 million. The company earns $-18,470,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. NuCana employs 21 workers across the globe.View Additional Information About NuCana.
What is NuCana's official website?
How can I contact NuCana?
NuCana's mailing address is 3 LOCHSIDE WAY, EDINBURGH X0, EH12 9DT. The company can be reached via phone at 44-0-13-1357-1111 or via email at [email protected]
MarketBeat Community Rating for NuCana (NASDAQ NCNA)
MarketBeat's community ratings are surveys of what our community members think about NuCana and other stocks. Vote "Outperform" if you believe NCNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NCNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
